Abstracts tagged "biosimilars"

Abstract Number: 549 • 2019 ACR/ARP Annual Meeting
US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey
Allan Gibofsky¹, Dorothy McCabe ² and Sam Badawi ², ¹Weill Cornell Medical College, New York, NY, ²Boehringer Ingelheim, Ridgefield, CT
Background/Purpose: A systematic review of survey literature from 2014-2018 found that clinicians in the US and Europe are cautious about biosimilar use (JMCP; 2019;25:102). We…
Abstract Number: 1115 • 2019 ACR/ARP Annual Meeting
Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
Bruno Emond ¹, Kay Sadik ², Marie-Hélène Lafeuille ¹, Willy Wynant ¹, Aurélie Côté-Sergent ¹, Patrick Lefebvre ¹, Kimberly Woodruff ² and Timothy Fitzgerald³, ¹Analysis Group, Inc, Montreal, QC, Canada, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Chronic inflammatory diseases (CIDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (PsO), ankylosing spondylitis (AS), Crohn's disease (CD), and ulcerative colitis…
Abstract Number: 1116 • 2019 ACR/ARP Annual Meeting
Non-medical Switching from Reference to Biosimilar Etanercept – No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data
Uta Kiltz¹, Styliani Tsiami ¹, Xenofon Baraliakos ² and Jürgen Braun ³, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Real-world data about switching patients from originator product to a biosimilars are important to assess and to document the outcome of switches in clinical…
Abstract Number: 1118 • 2019 ACR/ARP Annual Meeting
US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation
Ting-Chun Yeh¹, Yolaine Jeune-Smith ¹, Eli Phillips ¹, Ajeet Gajra ¹ and Bruce Feinberg ¹, ¹Cardinal Health Specialty Solutions, Dublin, OH
Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for…
Abstract Number: 2534 • 2018 ACR/ARHP Annual Meeting
Impact of Block Switch to Biosimilar Etanercept in Practice, Accross Different Rheumatic Diseases
Luisa Brites¹, Flavio Costa², João Freitas³, Mariana Luis⁴, Margarida Coutinho⁴, Mariana Santiago³, Cátia Duarte⁵, Maria Joao Salvador⁴ and José António P. da Silva⁶, ¹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ²Rheumatology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ³Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, ⁴Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁵Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁶Department of rheumatology, Centro Hospitalar e Universitário de Coimbra (SRHUC), Coimbra, Portugal
Background/Purpose: Biosimilars of biotechnological agents represent an important opportunity to increase accessibility to these medications. Clinicians still maintain reservations regarding the similarity of their efficacy…
Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra¹, Nagnath Khadke², Manjit Saluja³, Toktam Kainifard⁴ and Anuradha Venugopalan⁵, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatolgy, Consultant, Pune, India, ³Rheumatology, Research Co-ordinator, Pune, India, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…
Abstract Number: 216 • 2018 ACR/ARHP Annual Meeting
Inflectra and Remicade Use and Cost in Canada Under Provincial Drug Plans in 2016
Cristiano S. Moura¹, Denis Choquette², Gilles Boire³, Vivian P. Bykerk⁴, Carter Thorne⁵, Walter P. Maksymowych⁶, Peter Lakatos⁷, Talat Bessissow⁸, Larry Svenson⁹, Laura Targownik¹⁰, Waqqas Afif⁸ and Sasha Bernatsky¹¹, ¹The Centre for Outcomes Research and Evaluation (CORE), McGill University Health Centre, Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada, ³Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Hospital for Special Surgery, New York, NY, ⁵University of Toronto, Newmarket, ON, Canada, ⁶Department of Medicine, CaRE Arthritis and University of Alberta, Edmonton, Canada, Edmonton, AB, Canada, ⁷Medicine, Gastroenterology, McGill University, Montreal, QC, Canada, ⁸Gastroenterology, McGill University, Montreal, QC, Canada, ⁹Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁰Gastroenterology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Inflectra (infliximab) was the first biosimilar for inflammatory bowel disease and/or arthritis, approved by Health Canada on the belief that it is as safe…
Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Young Mo Kang², Wan-Hee Yoo³, Paul Emery⁴, Michael E Weinblatt⁵, Edward C. Keystone⁶, Mark C. Genovese⁷, Gihyun Myung⁸, Evelyn Hong⁸, Inyoung Baek⁸ and Jeehoon Ghil⁸, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), ⁴University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
Abstract Number: 977 • 2018 ACR/ARHP Annual Meeting
Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
Andrew Fell¹, Emma Carson¹, Gillian Coyle¹, Neil Martin¹, Jo Walsh¹ and Janet Gardner-Medwin², ¹Paediatic Rheumatology, Royal hospital for Children, Glasgow, United Kingdom, ²School of Medicine, Dentistry & Nursing, Child Health, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Original Reference Product (ORP) Infliximab lost market exclusivity in europe in early 2015. The Scottish National Health service (SNHS), runs a national procurement system…
Abstract Number: 1532 • 2018 ACR/ARHP Annual Meeting
Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
Paul Emery¹, Michael E Weinblatt², Josef S. Smolen³, Edward C. Keystone⁴, Mark C. Genovese⁵, Jiri Vencovsky⁶, Jonathan Kay⁷, Evelyn Hong⁸ and Jeehoon Ghil⁸, ¹University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Stanford University Medical Center, Palo Alto, CA, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ⁷UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. The phase III randomized, double-blind clinical studies comparing the efficacy and…
Abstract Number: 1769 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Biomimic Rituximab in Granulomatosis with Polyangiitis – Experience from a Single Tertiary Care Centre in India
Aman Sharma¹, Sakshi Mittal², GSRSNK Naidu³, Saket Jha², Manish Rathi⁴, Vikas Sharma², Arghya Chattopadhyay⁵, Varun Dhir⁶, Kusum Sharma⁷, Ranjana Minz⁸, Ritambhra Nada⁹ and Sanjay Jain¹⁰, ¹Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ²Internal Medicine, PGIMER, Chandigarh, India, ³PGIMER, cHANDIGARH, India, ⁴Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁵PGIMER, Chandigarh, India, ⁶Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ⁷Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ⁸Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ¹⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, CHANDIGARH, India
Background/Purpose: Though rituximab(RTX) has become a standard of care for remission induction and maintenance in Granulomatosis with Polyangiitis(GPA), there is very limited data on the…
Abstract Number: 1936 • 2018 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Piotr Wiland¹, Sławomir Jeka², Eva Dokoupilová^3,4, Juan Manuel Miranda Limón⁵, Julia Jauch-Lembach⁶, Anjali Thakur⁶, Halimuniyazi Haliduola⁶ and Norman B Gaylis⁷, ¹Wrocław Medical University, Wrocław, Poland, ²Collegium Medicum UMK, 2nd University Hospital, Bydgoszcz, Poland, ³MEDICAL PLUS s.r.o., Uherské Hradiště, Czech Republic, ⁴Faculty of Pharmacy, University of Veterinary and Pharmaceutical sciences, Brno, Czech Republic, ⁵RM Pharma Specialists, Mexico City, Mexico, ⁶Hexal AG, Holzkirchen, Germany, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: GP2017, a proposed adalimumab biosimilar, matched reference adalimumab (refADL) in preclinical and pharmacokinetics studies.1,2 The confirmatory efficacy and safety study in patients with plaque-type…
Abstract Number: 2154 • 2018 ACR/ARHP Annual Meeting
Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes
Hubert Marotte¹, NADIR MAMMAR² and Bruno Fautrel³, ¹University Hospital of Saint Etienne,, Saint Etienne, France, ²Pfizer, PARIS, France, ³Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S 1136, Sorbonne Université, GRC-UPMC 08, Paris, France
Background/Purpose: CT-P13 was the first monoclonal antibody biosimilar to infliximab (IFX) approved in France. Reflect trial has been set up to evaluate in real life…
Abstract Number: 2367 • 2018 ACR/ARHP Annual Meeting
Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)
Marc Scherlinger^1,2,3, Vincent Germain¹, Emmanuel Langlois⁴ and Thierry Schaeverbeke⁵, ¹Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ²FHU ACRONIM, Bordeaux, France, ³Rheumatology, UMR CNRS 5164 - Immunoconcept, France, Bordeaux, France, ⁴CNRS-UMR 5116 Centre Emile Durkheim, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Biosimilars represent major potential savings while preserving treatment quality. However, few data are known on how to address the switch from originator to biosimilar…
Abstract Number: 2384 • 2018 ACR/ARHP Annual Meeting
Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany
Jens Klotsche¹, Martina Niewerth¹, Gerd Horneff² and Kirsten Minden^3,4, ¹Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Department of Pediatrics, Asklepios Clinics St. Augustin, Sankt Augustin, Germany, ³Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁴German Rheumatism Research Center, Berlin, Germany
Background/Purpose: The first biosimilars have been approved for the treatment of juvenile idiopathic arthritis (JIA) in the last two years. To date, only a few…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].